CAR T-CELL THERAPY

Latest News

CARTITUDE-1 Update: Cilta-Cel Maintains Benefit in R/R Multiple Myeloma
CARTITUDE-1 Update: Cilta-Cel Maintains Benefit in R/R Multiple Myeloma

March 21st 2023

At a prespecified analysis of the CARTITUDE-1 trial with a median follow-up of approximately 28 months, treatment with cilta-cel continued to elicit positive responses and maintained a favorable risk/benefit profile for patients with multiple myeloma.

Leveraging ctDNA to Predict Response in Patients With Myeloma Receiving CAR T Cells
Leveraging ctDNA to Predict Response in Patients With Myeloma Receiving CAR T Cells

March 20th 2023

CAR T-Cell Therapy With CYAD-01 Shows Efficacy in Myeloid Malignancies
CAR T-Cell Therapy With CYAD-01 Shows Efficacy in Myeloid Malignancies

March 13th 2023

Brexu-cel Generates Durable Responses and Survival Benefits in R/R B-ALL
Brexu-cel Generates Durable Responses and Survival Benefits in R/R B-ALL

February 22nd 2023

CD22-Directed CAR T-cell Therapy Overcomes CD19 Relapse in LBCL With High CR Rates
CD22-Directed CAR T-cell Therapy Overcomes CD19 Relapse in LBCL With High CR Rates

February 17th 2023

Video Series
Video Interviews

More News